Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

274
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
274
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic Therapy of Psoriasis in Children-Proposal of an Algorithm for Interdisciplinary Teamwork.

Journal of clinical medicine·2024
Same author

Evaluation of skin cancer screening in Germany - a Microsimulation.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2024
Same author

Assessment and Monitoring of the Wound Micro-Environment in Chronic Wounds Using Standardized Wound Swabbing for Individualized Diagnostics and Targeted Interventions.

Biomedicines·2024
Same author

Epidemiology and Healthcare of Juvenile and Late-Onset Acne: Claims Data Analysis.

Dermatology and therapy·2024
Same author

Vaccination Rates in Patients with Chronic Inflammatory Skin Diseases and Immunomodulatory Systemic Therapies-Vaccinations against SARS-CoV-2, Influenza Virus or Varicella Zoster Virus.

Life (Basel, Switzerland)·2024
Same author

Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis.

Dermatology and therapy·2024

Related Experiment Video

Updated: May 1, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.4K

Biosimilars in psoriasis: what can we expect?

Marc Alexander Radtke1, Matthias Augustin

  • 1CVderm - Center of Excellence for Health Services Research in Dermatology, IVDP - Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Hamburg Dermatologie, Dermatology Practice, Hamburg, Germany.

Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|April 5, 2014
PubMed
Summary

Biosimilars offer identical amino acid sequences to original biopharmaceuticals, becoming crucial in dermatology as patents expire. Regulatory requirements for clinical bioequivalence differ between the FDA and EMA, necessitating clear evidence for patient safety before market entry.

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

1.1K

Related Experiment Videos

Last Updated: May 1, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.4K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

1.1K

Area of Science:

  • Biotechnology and Pharmaceutical Sciences
  • Dermatology
  • Regulatory Affairs

Background:

  • Biosimilars, biotechnologically produced drugs with identical amino acid sequences to reference biopharmaceuticals, are gaining clinical and economic importance.
  • Expiring patents for biologics used in psoriasis treatment, such as adalimumab and etanercept, will increase the relevance of biosimilars in dermatology.
  • Regulatory bodies like the EMA and FDA have established guidelines for assessing biosimilar bioequivalence, risks, and benefits.

Purpose of the Study:

  • To analyze the clinical, economic, and healthcare implications of biosimilars in dermatology.
  • To compare the regulatory requirements for biosimilar approval by the FDA and EMA, focusing on clinical bioequivalence.
  • To emphasize the need for robust evidence-based regulatory conditions to ensure biosimilar quality, safety, and efficacy.

Main Methods:

  • Comparative analysis of FDA and EMA guidelines for biosimilar assessment.
  • Review of preclinical and clinical requirements for bioequivalence.
  • Evaluation of the impact of patent expirations on biologic drug markets.

Main Results:

  • Preclinical requirements for biosimilar assessment are largely similar between the FDA and EMA.
  • Significant differences exist in the formal requirements for clinical bioequivalence, including efficacy and safety evaluations, between the two agencies.
  • The increasing number of patent expirations necessitates a thorough regulatory framework for biosimilars.

Conclusions:

  • Biosimilars hold potential as cost-effective alternatives in dermatology, provided they offer equivalent value to patients.
  • Establishing clear, evidence-based regulatory conditions is paramount before biosimilars enter the market.
  • Prioritizing unequivocal proof of bioequivalence, quality, and patient safety over economic benefits is essential for successful biosimilar integration.